173 related articles for article (PubMed ID: 35759980)
1. Analysis of color vision and cognitive function in first-episode schizophrenia before and after antipsychotic treatment.
Duan L; Tian C; Fu C; He J; Dai J; Shao X; Zhu G
J Psychiatr Res; 2022 Aug; 152():278-288. PubMed ID: 35759980
[TBL] [Abstract][Full Text] [Related]
2. Study on the Correlation Between Iris Characteristics and Schizophrenia.
Tian C; Duan L; Fu C; He J; Dai J; Zhu G
Neuropsychiatr Dis Treat; 2022; 18():811-820. PubMed ID: 35431547
[TBL] [Abstract][Full Text] [Related]
3. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
Lindenmayer JP; Khan A; Iskander A; Abad MT; Parker B
J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
[TBL] [Abstract][Full Text] [Related]
4. Brain-derived neurotrophic factor as a biomarker for cognitive recovery in acute schizophrenia: 12-week results from a prospective longitudinal study.
Zhang Y; Fang X; Fan W; Tang W; Cai J; Song L; Zhang C
Psychopharmacology (Berl); 2018 Apr; 235(4):1191-1198. PubMed ID: 29392373
[TBL] [Abstract][Full Text] [Related]
5. [Cognition, schizophrenia and the effect of antipsychotics].
Stip E
Encephale; 2006; 32(3 Pt 1):341-50. PubMed ID: 16840928
[TBL] [Abstract][Full Text] [Related]
6. A randomized controlled trial of olanzapine improving memory deficits in Han Chinese patients with first-episode schizophrenia.
Wang CH; Li Y; Yang J; Su LY; Geng YG; Li H; Wang JK; Mu JL
Schizophr Res; 2013 Mar; 144(1-3):129-35. PubMed ID: 23352776
[TBL] [Abstract][Full Text] [Related]
7. An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes.
Cheng Z; Yuan Y; Han X; Yang L; Cai S; Yang F; Lu Z; Wang C; Deng H; Zhao J; Xiang Y; Correll CU; Yu X
J Psychopharmacol; 2019 Oct; 33(10):1227-1236. PubMed ID: 31487208
[TBL] [Abstract][Full Text] [Related]
8. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?
Goldberg TE; Goldman RS; Burdick KE; Malhotra AK; Lencz T; Patel RC; Woerner MG; Schooler NR; Kane JM; Robinson DG
Arch Gen Psychiatry; 2007 Oct; 64(10):1115-22. PubMed ID: 17909123
[TBL] [Abstract][Full Text] [Related]
9. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study.
Cuesta MJ; Peralta V; Zarzuela A
Schizophr Res; 2001 Mar; 48(1):17-28. PubMed ID: 11278151
[TBL] [Abstract][Full Text] [Related]
10. Associations between macular pigment, iris color and reflectance, ethnicity, and color vision: An observational study.
Garakani R; Ng JS
PLoS One; 2019; 14(8):e0220940. PubMed ID: 31393943
[TBL] [Abstract][Full Text] [Related]
11. [Cognitive effectiveness of risperidone and olanzapine in first-episode schizophrenia].
Zhao J; Zhang Y; Chao YY; Ma J; Yang YF; Zhao JY; Du YH; Li WW; Song XQ; Lü LX
Zhonghua Yi Xue Za Zhi; 2016 Oct; 96(37):2960-2964. PubMed ID: 27760654
[No Abstract] [Full Text] [Related]
12. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Yıldız M; Osman E
Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia.
Riedel M; Müller N; Spellmann I; Engel RR; Musil R; Valdevit R; Dehning S; Douhet A; Cerovecki A; Strassnig M; Möller HJ
Eur Arch Psychiatry Clin Neurosci; 2007 Oct; 257(7):402-12. PubMed ID: 17629725
[TBL] [Abstract][Full Text] [Related]
14. Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study.
Takeuchi H; Suzuki T; Remington G; Bies RR; Abe T; Graff-Guerrero A; Watanabe K; Mimura M; Uchida H
Schizophr Bull; 2013 Sep; 39(5):993-8. PubMed ID: 23821768
[TBL] [Abstract][Full Text] [Related]
15. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
16. Early prediction of clinical response in first episode schizophrenia (FES) patients receiving olanzapine.
Subeesh V; Maheswari E; Singh H; Saraswathy GR; Reddy N; Chiranjeevi P
Int J Psychiatry Clin Pract; 2020 Sep; 24(3):309-314. PubMed ID: 32338556
[No Abstract] [Full Text] [Related]
17. Reduced connectivity in anterior cingulate cortex as an early predictor for treatment response in drug-naive, first-episode schizophrenia: A global-brain functional connectivity analysis.
Li H; Ou Y; Liu F; Chen J; Zhao J; Guo W; Fan X
Schizophr Res; 2020 Jan; 215():337-343. PubMed ID: 31522869
[TBL] [Abstract][Full Text] [Related]
18. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
[TBL] [Abstract][Full Text] [Related]
19. Volume increases in putamen associated with positive symptom reduction in previously drug-naive schizophrenia after 6 weeks antipsychotic treatment.
Li M; Chen Z; Deng W; He Z; Wang Q; Jiang L; Ma X; Wang Y; Chua SE; Cheung C; McAlonan GM; Sham PC; Collier DA; Gong Q; Li T
Psychol Med; 2012 Jul; 42(7):1475-83. PubMed ID: 22030695
[TBL] [Abstract][Full Text] [Related]
20. Perceptual and cognitive effects of antipsychotics in first-episode schizophrenia: the potential impact of GABA concentration in the visual cortex.
Kelemen O; Kiss I; Benedek G; Kéri S
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Dec; 47():13-9. PubMed ID: 23954737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
